诺瓦瓦克斯新冠疫苗(NVX-CoV2373)的获益-风险评估
该获益-风险评估旨在判断接种NVX-CoV2373的获益是否超过心肌炎/心包炎风险,使用该疫苗临床研究中的心肌炎/心包炎病例数据、2023年初mRNA新冠疫苗针对主要SARS-CoV-2毒株有效性的真实世界数据及美国近期COVID-19疾病负担数据。分析显示,每10万接种者中估计预防1805例COVID-19病例,而估计增加5.3例心肌炎/心包炎病例,预防的COVID-19住院和死亡数也大于疫苗相关心肌炎/心包炎住院和死亡数,表明NVX-CoV2373具有正向获益-风险平衡。
要点
- 每10万接种者中,NVX-CoV2373估计预防1805例COVID-19病例,估计增加5.3例心肌炎/心包炎病例。
- 预防的COVID-19住院和死亡数大于疫苗相关心肌炎/心包炎住院和死亡数。
- 分析表明NVX-CoV2373具有正向获益-风险平衡。
核心结论
- 分析表明NVX-CoV2373具有正向获益-风险平衡。
研究设计与样本
- 对NVX-CoV2373进行获益-风险评估,使用该疫苗临床研究中的心肌炎/心包炎病例数据、2023年初mRNA新冠疫苗针对主要SARS-CoV-2毒株有效性的真实世界数据及美国近期COVID-19疾病负担数据。
主要发现
- 每10万接种者中,NVX-CoV2373估计预防1805例COVID-19病例,而估计增加5.3例心肌炎/心包炎病例。
- 预防的COVID-19住院和死亡数也大于疫苗相关心肌炎/心包炎住院和死亡数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A benefit-risk assessment of NVX-CoV2373, a vaccine to prevent COVID-19, was conducted to determine if the benefits of vaccination outweigh the risks of myocarditis/pericarditis. This analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373 clinical studies, real-world data of mRNA COVID vaccine effectiveness against predominant SARS-CoV-2 strains in early 2023, and recent COVID-19 burden of disease data from the United States. The benefits of NVX-CoV2373 vaccination were estimated as the number of COVID-19 cases, hospitalizations, and deaths prevented. The risks of myocarditis/pericarditis cases and related hospitalizations and deaths occurring within 7 days of vaccination were also estimated. In our analysis, vaccination with NVX-CoV2373, per 100,000 vaccinated, resulted in an estimated 1805 COVID-19 cases prevented compared with an estimated 5.3 excess myocarditis/pericarditis cases. The number of COVID-19 hospitalizations and deaths prevented were also greater than vaccine-associated myocarditis/pericarditis hospitalizations and deaths. Our analysis indicates a positive benefit-risk balance for NVX-CoV2373.
引用
- Fix J, Christopher Mast T, Smith K, et al. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373). Vaccine. 2024. PMID: 38494410. doi:10.1016/j.vaccine.2024.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。